BCEIE › News › NOVARTIND

Fund raising

Novartis India plans rights issue

Novartis India (BSE: NOVARTIND) said it has taken up rights issue. The company is valued at about ₹3,754 crore.

BCEIE News Desk · Published 16 Nov 2026, 03:37 pm IST · Filing received 16 Nov 2026, 03:21 pm IST

What happened

Novartis India (BSE: NOVARTIND) informed the stock exchanges on 16 November 2026 at 03:21 PM that it has taken up rights issue.

From the filing: "Newspaper Publication w.r.t. the dispatch of Letter of Offer and issue materials for the Rights Issue of the Equity Shares of the Company."

Company snapshot

Novartis India is a small-cap company, with a market value of about ₹3,754 crore.

The stock last traded at ₹1,520.4, against a 52-week range of ₹672.3–₹2,391.3 (36.4% below the high).

Before this filing the shares had moved −9.1% over the month and +13.7% over three months. Average daily turnover over the last 20 sessions was about ₹7.37 crore.

Promoters held 70.68% at the end of Q2 FY27. Foreign institutions owned 1.22% and domestic institutions 1.50%.

Quarterly results (standalone, ₹ crore)
QuarterRevenueNet profitEPS (₹)
Q2 FY269024.29.81
Q3 FY268616.16.52
Q4 FY269125.310.23
Q1 FY2710432.213.05
Q2 FY2756-77.5-31.41

What history shows

BCEIE's records show 5 previous fund raising filings from the company since May 2026.

After those filings, the stock gained 2.7% on average the next trading day (5 filings with price data).

Market-wide, 1,814 fund raising filings with an impact score of 50 or more saw an average next-day move of +0.3%, with 48% rising.

Past reactions describe what happened before; they are not a forecast.

Earlier filings of this kind
DateFilingNext day5 days
5 Nov 2026Submission of the Letter of Offer in connection with the proposed…+6.0%—
4 Nov 2026Intimation is hereby given that the record date for determining the…+2.6%—
4 Nov 2026Outcome of the meeting of the Rights Issue Committee held today i.e.…+2.6%—
8 Oct 2026The Board of Directors of the Company Evonile Pharma Limited…+1.3%—
8 Oct 2026The Board of Directors of Evonile Pharma Limited (formally known as…+1.3%—

What to watch

  • How the money raised is used and, for equity instruments, the dilution for existing shareholders.

In the news

Recent coverage elsewhere (links open the original publisher):

Source

Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.

More on Novartis India Limited